Hypercholesterolemia has been identified as a risk factor for Alzheimer’s disease. In this study, rabbits were fed either a cholesterol diet or normal chow diet for 24 months. At endpoint, in vivo MRI was performed at the field strength of 3 Tesla using fast imaging employing steady state acquisition without (FIESTA) or with susceptibility-weighted post-processing (SWI-FIESTA) and susceptibility-weighted imaging with multi-echo acquisition (SWAN). This imaging revealed signal voids/hypointensities throughout the cortex, sub-cortex, and hippocampus of cholesterol-fed animals compared to control animals. Quantitative image analysis corroborated these qualitative findings and highlighted that SWI processing of FIESTA images significantly improved the detectability of plaques (p < 0.05). Aβ immunostaining and Prussian blue staining for iron demonstrated that the voids in MR images corresponded to iron-laden Aβ-positive plaques. This study demonstrates non-invasive in vivo visualization of Aβ plaques in a diet-induced large animal model of Alzheimer’s disease. This work lays the foundation for future work focusing on longitudinal monitoring of plaque formation in this model and the effects of diet or drug interventions.
KhachaturianZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol42, 1097-1105.
2.
QiuC, KivipeltoM, von StraussE (2009) Epidemiology of Alzheimer’sdisease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci11, 111-128.
3.
Alzheimer’s Association (2016) 2016 Alzheimer’s disease facts and figures. Alzheimers Dement12, 459-509.
4.
SpiresTL, HymanBT (2005) Transgenic models of Alzheimer’s disease: Learning from animals. NeuroRx2, 423-437.
5.
LiXY, MenWW, ZhuH, LeiJF, ZuoFX, WangZJ, ZhuZH, BaoXJ, WangRZ (2016) Age- and brain region-specific changes of glucose metabolic disorder, learning, and memory dysfunction in early Alzheimer’s disease assessed in APP/PS1 transgenic mice using18F-FDG-PET, Int J Mol Sci17, E1707.
6.
PuzzoD, GulisanoW, PalmeriA, ArancioO (2015) Rodent models for Alzheimer’s disease drug discovery. Expert Opin Drug Discov10, 703-711.
7.
GrossmanI, LutzMW, CrenshawDG, SaundersAM, BurnsDK, RosesAD (2010) Alzheimer’s disease: Diagnostics, prognostics and the road toprevention. EPMA J1, 293-303.
8.
GreenlandP, BowleyNL, FrenchCA, MeiklejohnB, GaglianoS, SparksCE (1990) Precision and accuracy of a portable blood analyzer systemduring cholesterol screening. Am J Public Health80, 181-184.
9.
LedesmaMD, DottiCG (2012) Peripheral cholesterol, metabolic disorders and Alzheimer’s disease. Front Biosci (Elite Ed)4, 181-194.
10.
KalariaRN (2002) Small vessel disease and Alzheimer’s dementia: Pathological considerations. Cerebrovasc Dis13Suppl2, 48-52.
11.
JarvikGP, AustinMA, FabsitzRR, AuwerxJ, ReedT, ChristianJC, DeebS (1994) Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceridelevels: Longitudinal apolipoprotein E genotype effects. Genet Epidemiol11, 375-384.
12.
NotkolaIL, SulkavaR, PekkanenJ, ErkinjunttiT, EhnholmC, KivinenP, TuomilehtoJ, NissinenA (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology17, 14-20.
13.
KarchCM, GoateAM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry77, 43-51.
14.
Mendoza-OlivaA, ZepedaA, AriasC (2014) The complex actions ofstatins in brain and their relevance for Alzheimer’s disease treatment: An analytical review. Curr Alzheimer Res11, 817-833.
15.
SparksDL, ScheffSW, HunsakerJC3rd, LiuH, LandersT, GrossDR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity inthe brains of rabbits with dietary cholesterol. Exp Neurol126, 88-94.
16.
SparksDL (2008) The early and ongoing experience with the cholesterol-fed rabbit as a model of Alzheimer’s disease: The old, the new and the pilot. J Alzheimers Dis15, 641-656.
17.
SparksDL, LiuH, GrossDR, ScheffSW (1995) Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci Lett187, 142-144.
18.
ReisiP, DashtiGR, ShabrangM, RashidiB (2014) The effect of vitamin E on neuronal apoptosis in hippocampal dentate gyrus inrabbits fed with high-cholesterol diets. Adv Biomed Res3, 42.
19.
HallAM, RobersonED (2012) Mouse models of Alzheimer’s disease. Brain Res Bull88, 3-12.
20.
StreitWJ, SparksDL (1997) Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med75, 130-138.
DaleySJ, HerderickEE, CornhillJF, RogersKA (1994) Cholesterol-fed and casein-fed rabbit models of atherosclerosis. Part 1: Differing lesion area and volume despite equal plasmacholesterol levels. Arterioscler Thromb14, 95-104.
23.
DaleySJ, KlempKF, GuytonJR, RogersKA (1994) Cholesterol-fed andcasein-fed rabbit models of atherosclerosis. Part 2: Differing morphological severity of atherogenesis despite matched plasma cholesterol levels. Arterioscler Thromb14, 105-141.
24.
CiminiM, BoughnerDR, RonaldJA, AldingtonL, RogersKA (2005) Development of aortic valve sclerosis in a rabbit model of atherosclerosis: An immunohistochemical and histological study. J Heart Valve Dis14, 365-375.
25.
HamiltonAM, RogersKA, BelisleAJL, RonaldJA, RuttBK, WeisslederR, BoughnerDR (2010) Early identification of aortic valve sclerosisusing iron oxide enhanced MRI. J Magn Reson Imaging31, 110-116.
26.
RonaldJA, ChenY, BelisleAJL, HamiltonAM, RogersKA, HegeleRA, MisselwitzB, RuttBK (2009) Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stabilityusing MRI. Circ Cardiovasc Imaging2, 226-234.
27.
RonaldJA, WalcariusR, RobinsonJF, HegeleRA, RuttBK, RogersKA (2007) MRI of early- and late-stage arterial remodeling in alow-level cholesterol-fed rabbit model of atherosclerosis. J Magn Reson Imaging26, 1010-1019.
28.
ChenY, HamiltonAM, ParkinsKM, WangJX, RogersKA, ZeinehMM, RuttBK, RonaldJA (2016) MRI and histopathologic study of a novelcholesterol-fed rabbit model of xanthogranuloma. J Magn Reson Imaging44, 673-682.
29.
MeadowcroftMD, ConnorJR, SmithMB, YangQX (2009) MRI andhistological analysis of beta-amyloid plaques in both lzheimer’s disease and APP/PS1 transgenic mice. J Magn Reson Imaging29, 997-1007humanA.
30.
ZeinehMM, ChenY, KitzlerHH, HammondR, VogelH, RuttBK (2015) Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol Aging36, 2483-2500.
31.
SantinMD, DebeirT, BridalSL, RooneyT, DhenainM (2013) Fast in vivo imaging of amyloid plaques using mu-MRI Gd-staining combined with ultrasound-induced blood-brain barrier opening. Neuroimage79, 288-294.
32.
WadghiriYZ, HoangDM, WisniewskiT, SigurdssonEM (2012) In vivomagnetic resonance imaging of amyloid-beta plaques in mice. Methods Mol Biol849, 435-451.
33.
JackCR Jr, GarwoodM, WengenackTM, BorowskiB, CurranGL, LinJ, AdrianyG, GrohnOHJ, GrimmR, PodusloJF (2004) In vivovisualization of Alzheimer’s amyloid plaques by magnetic resonanceimaging in transgenic mice without a contrast agent. Magn Reson Med52, 1263-1271.
RonaldJA, ChenJW, ChenY, HamiltonAM, RodriguezE, ReynoldsF, HegeleRA, RogersKA, QuerolM, BogdanovA, WeisslederR, RuttBK (2009) Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation120, 592-599.
36.
HaackeEM, MittalS, WuZ, NeelavalliJ, ChengYC (2009) Susceptibility-weighted imaging: Technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol30, 19-30.
37.
HeynC, RonaldJA, RamadanSS, SnirJA, BarryAM, MacKenzieLT, MikulisDJ, PalmieriD, BronderJL, SteegPS, YonedaT, MacDonaldIC, ChambersAF, RuttBK, FosterPJ (2006) In vivo MRI of cancercell fate at the single-cell level in a mouse model of breast cancermetastasis to the brain. Magn Reson Med56, 1001-1010.
38.
HayashidaY, KakedaS, HiaiY, IdeS, OgasawaraA, OokiH, WatanabeK, NishimuraJ, OhnariN, KorogiY (2014) Diagnosis of intracranialhemorrhagic lesions: Comparison between 3D-SWAN (3D T2*-weightedimaging with multi-echo acquisition) and 2D-T2*-weighted imaging. Acta Radiol55, 201-207.
CosottiniM, FrosiniD, PesaresiI, CostagliM, BiagiL, CeravoloR, BonuccelliU, TosettiM (2014) MR imaging of the substantia nigra at7 T enables diagnosis of Parkinson disease. Radiology271, 831-838.
41.
CosottiniM, FrosiniD, PesaresiI, DonatelliG, CecchiP, CostagliM, BiagiL, CeravoloR, BonuccelliU, TosettiM (2015) Comparison of 3T and 7T susceptibility-weighted angiography of the substantianigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol36, 461-466.
42.
BenvenisteH, EinsteinG, KimKR, HuletteC, JohnsonGA (1999) Detection of neuritic plaques in Alzheimer’s disease by magneticresonance microscopy. Proc Natl Acad Sci U S A96, 14079-14084.
43.
JackCR Jr, GarwoodM, WengenackTM, BorowskiB, CurranGL, LinJ, AdrianyG, GrohnOH, GrimmR, PodusloJF (2004) In vivovisualization of Alzheimer’s amyloid plaques by magnetic resonanceimaging in transgenic mice without a contrast agent. Magn Reson Med52, 1263-1271.
44.
LeeSP, FalangolaMF, NixonRA, DuffK, HelpernJA (2004) Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer’s disease using MR microscopy without contrast reagents. Magn Reson Med52, 538-544.
45.
ZhangJ, YarowskyP, GordonMN, Di CarloG, MunireddyS, van ZijlPC, MoriS (2004) Detection of amyloid plaques in mouse models ofAlzheimer’s disease by magnetic resonance imaging. Magn ResonMed51, 452-457.
46.
BorthakurA, GurT, WheatonAJ, CorboM, TrojanowskiJQ, LeeVM, ReddyR (2006) In vivo measurement of plaque burden in a mouse model of Alzheimer’s disease. J Magn Reson Imaging24, 1011-1017.
47.
BraakmanN, MatysikJ, vanDuinen SG, VerbeekF, SchliebsR, deGrootHJ, AliaA (2006) Longitudinal assessment of Alzheimer’s beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging24, 530-536.
48.
ChamberlainR, ReyesD, CurranGL, MarjanskaM, WengenackTM, PodusloJF, GarwoodM, JackCRJr (2009) Comparison of amyloidplaque contrast generated by T2-weighted, T2*-weighted, andsusceptibility-weighted imaging methods in transgenic mouse modelsof Alzheimer’s disease. Magn Reson Med61, 1158-1164.
49.
WadghiriYZ, HoangDM, WisniewskiT, SigurdssonEM (2012) In vivomagnetic resonance imaging of amyloid-beta plaques in mice. Methods Mol Biol849, 435-451.
50.
WadghiriYZ, LiJ, WangJ, HoangDM, SunY, XuH, TsuiW, LiY, BoutajangoutA, WangA, deLeon M, WisniewskiT (2013) Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer’s disease transgenic mice using magnetic resonance microimaging., PLoS One8, e57097.
GrohnOH, KettunenMI, PenttonenM, OjaJM, van ZijlPC, KauppinenRA (2000) Graded reduction of cerebral blood flow in rat as detected by the nuclear magnetic resonance relaxation time T2: A theoreticaland experimental approach. J Cereb Blood Flow Metab20, 316-326.
53.
BakshiR, BenedictRH, BermelRA, CaruthersSD, PuliSR, TjoaCW, FabianoAJ, JacobsL (2002) T2 hypointensity in the deep gray matterof patients with multiple sclerosis: A quantitative magneticresonance imaging study. Arch Neurol59, 62-68.
PoppJ, MeichsnerS, KolschH, LewczukP, MaierW, KornhuberJ, JessenF, LutjohannD (2013) Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer’s disease. Biochem Pharmacol86, 37-42.
57.
KuoYM, EmmerlingMR, BisgaierCL, EssenburgAD, LampertHC, DrummD, RoherAE (1998) Elevated low-density lipoprotein in Alzheimer’sdisease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun252, 711-715.
58.
KoudinovAR, BerezovTT, KoudinovaNV (2002) Cholesterol and Alzheimer’s disease: Is there a link?Neurology58, 1135.
59.
PetanceskaSS, DeRosaS, SharmaA, DiazN, DuffK, TintSG, RefoloLM, PappollaM (2003) Changes in apolipoprotein E expression inresponse to dietary and pharmacological modulation of cholesterol. J Mol Neurosci20, 395-406.
60.
BarrettPJ, SongYL, Van HornWD, HustedtEJ, SchaferJM, HadziselimovicA, BeelAJ, SandersCR (2012) The amyloid precursorprotein has a flexible transmembrane domain and binds cholesterol. Science336, 1168-1171.
61.
Di ScalaC, YahiN, LelievreC, GarmyN, ChahinianH, FantiniJ (2013) Biochemical identification of a linear cholesterol-bindingdomain with in Alzheimer’s beta amyloid peptide. Acs Chemical Neuroscience4, 509-517.
62.
NicholsonAM, FerreiraA (2009) Increased membrane cholesterol mightrender mature hippocampal neurons more susceptible tobeta-amyloid-induced calpain activation and tau toxicity. J Neurosci29, 4640-4651.
63.
HayashiH, IgbavboaU, HamanakaH, KobayashiM, FujitaSC, WoodWG, YanagisawaK (2002) Cholesterol is increased in the exofacialleaflet of synaptic plasma membranes of human apolipoprotein E4knock-in mice. Neuroreport13, 383-386.
64.
KojroE, GimplG, LammichS, MarzW, FahrenholzF (2001) Lowcholesterol stimulates the non amyloidogenic pathway by its effect onthe alpha-secretase ADAM 10. Proc Natl Acad Sci U S A98, 5815-5820.
